DNA Synthesis Market
Number of pages: 100 | Report Format: PDF | Published date: June 26, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.01 billion |
|
Revenue Forecast in 2031 |
US$ 14.56 billion |
|
CAGR |
19.13% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Service Type, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global DNA synthesis market was valued at US$ 3.01 billion in 2022 and is expected to register a revenue CAGR of 19.13% to reach US$ 14.56 billion by 2031.
DNA Synthesis Market Fundamentals
DNA synthesis, also known as DNA replication or DNA replication, is the process by which a cell duplicates its DNA to produce two identical copies. It is a fundamental process that occurs in all living organisms and is essential for cell division and the transmission of genetic information from one generation to the next. DNA synthesis occurs during the cell cycle's S phase (synthesis phase), which is part of the interphase. The DNA synthesis market is likely to expand in future years as breakthroughs in synthetic biology and gene editing methods drive the development of new applications for synthetic DNA.
DNA Synthesis Market Dynamics
Synthetic biology heavily relies on DNA synthesis, which involves designing and constructing new biological parts, devices, and systems. As synthetic biology continues to expand and find applications in various fields, such as medicine, agriculture, energy, and environmental conservation, the demand for DNA synthesis increases. The ability to synthesize customized DNA sequences plays a crucial role in enabling the development of novel biotechnological products and solutions. For instance, bit.bio, a leading synthetic biology company, successfully achieved a significant milestone in the production of human cells. Leveraging their innovative opti-oxTM 1-based transcription factor reprogramming technology, they have attained unprecedented precision and consistency in their manufacturing process for induced pluripotent stem cells (iPSC)-derived cell products. This achievement establishes a new industry standard for manufacturing human cells, showcasing bit.bio's commitment to excellence and advancements in synthetic biology.
Moreover, DNA synthesis is crucial in developing novel therapeutic approaches, including gene therapies, mRNA-based therapies, and DNA vaccines. These emerging fields leverage synthetic DNA constructs for delivering therapeutic agents and modulating gene expression. The expanding pipeline of gene and cell-based therapies drives the demand for the global DNA synthesis market. Furthermore, the field of DNA synthesis continues to advance with the development of innovative technologies. Novel synthesis methods, such as microarray-based synthesis, oligonucleotide synthesis platforms, and enzymatic synthesis, offer improved efficiency, scalability, and cost-effectiveness. These technological advancements propel the growth of the global DNA synthesis market by enabling higher throughput and increased customization capabilities.
However, despite the decreasing costs of DNA synthesis, it can still be relatively expensive, especially for large-scale projects or organizations with limited budgets. The cost of synthesizing longer DNA sequences or complex gene constructs can challenge researchers and industries seeking to utilize DNA synthesis extensively. Moreover, DNA synthesis is not completely error-free, and the accuracy of synthesized DNA sequences can vary depending on the synthesis method and platform used. Maintaining high-quality control standards and minimizing errors during DNA synthesis is crucial, especially for applications that require precise genetic manipulation or gene editing. Quality control measures, such as sequencing verification and purification processes, add to DNA synthesis’s overall cost and time. Cost constraints, error rates, and quality control are some of the restraints impeding the overall market growth.
DNA Synthesis Market Ecosystem
The global DNA synthesis market is analyzed from the following perspectives: service type, application, end user, and region.
DNA Synthesis Market by Service Type
Based on the service type, the global DNA synthesis market is segmented into gene synthesis and oligonucleotide synthesis.
The oligonucleotide synthesis segment dominated the market with a top revenue share of 56% in 2022. Oligonucleotides are short sequences of DNA or RNA, typically ranging from a few nucleotides up to about 200 nucleotides in length. Oligonucleotide DNA synthesis involves chemically synthesizing custom-designed DNA sequences with precise nucleotide sequences and modifications. Oligonucleotide DNA synthesis enables the precise customization and design of DNA sequences for various applications. Researchers and industries can order oligonucleotides with specific nucleotide sequences, lengths, and modifications tailored to their experimental or commercial needs. These custom-designed oligonucleotides are valuable tools in molecular biology research, diagnostics, therapeutics, and other fields.
Oligonucleotides have gained significant attention in the development of therapeutics. Different oligonucleotides, such as antisense oligonucleotides, siRNAs (small interfering RNAs), and aptamers, can be synthesized for targeted gene regulation, gene silencing, and molecular interactions. Oligonucleotide-based therapeutics hold promise for treating genetic disorders, cancers, and viral infections. DNA synthesis enables the production of specific and modified oligonucleotides optimized for therapeutic efficacy. Continuous research has been conducted to improve the overall oligonucleotide synthesis. In March 2023, Ansa Biotechnologies Inc. successfully synthesized the world's longest DNA oligonucleotide in a single synthesis. Ansa produced a 1005-base long oligonucleotide with industry-leading precision.
DNA Synthesis Market by Application
Based on the application, the global DNA synthesis market is segmented into diagnostics, research & development, and therapeutics.
The research & development segment dominated the market with a maximum revenue share of 41% in 2022, owing to rising research and development activities for drug development. R&D efforts in DNA synthesis focus on advancing the underlying technologies and methodologies in synthesizing DNA sequences. This includes exploring new synthesis methods, improving the efficiency and fidelity of DNA synthesis, enhancing scalability, and reducing costs. Continuous research and development enable the development of innovative DNA synthesis platforms and tools that facilitate more efficient and precise DNA synthesis. R&D activities aim to optimize the DNA synthesis process, improving key parameters such as yield, speed, and scalability. Researchers work on streamlining and automating the synthesis workflow, optimizing reaction conditions, and developing novel purification and quality control techniques. Process optimization helps enhance DNA synthesis's reliability, scalability, and cost-effectiveness, making it more accessible and applicable across various fields. These factors contribute to the growth of the research & development segment.
DNA Synthesis Market by End User
Based on the end user, the global DNA synthesis market is segmented into academic and research institutes, biopharmaceutical companies, and contract research organizations.
The biopharmaceutical companies segment is a key player in the DNA synthesis market, with the largest revenue share of 42% in 2022. Biopharmaceutical companies are involved in researching, developing, and commercializing therapeutic products derived from biological sources, including DNA-based therapeutics. Biopharmaceutical companies utilize DNA synthesis to optimize and scale up the production of DNA constructs used in manufacturing biopharmaceuticals. This includes the synthesis of plasmids, viral vectors, and other DNA-based components that serve as crucial elements in bioproduction processes. DNA synthesis technologies are vital in streamlining manufacturing processes, improving yields, and ensuring consistent quality and purity of DNA-based products. These overall factors contribute to the growth of the biopharmaceutical companies segment.
DNA Synthesis Market by Region
Geographically, the global DNA synthesis market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global DNA synthesis market with the largest revenue share of 42% in 2022, attributed to rising gene therapy-based drugs. Additionally, companies across the region are continuously involved in partnerships, mergers, and acquisitions, which are also expected to improve the DNA synthesis market outlook. For instance, in January 2021, Codex DNA, Inc., a leading company specializing in automated solutions for the on-demand synthesis of genes and mRNA, entered into a strategic collaboration and licensing agreement with Pfizer. This partnership aims to provide Pfizer access to Codex DNA's innovative EDS technology while allowing Codex DNA to develop further the technology for potential application in Pfizer's mRNA-based vaccines and other biopharmaceutical products.
DNA Synthesis Market Competitive Landscape
The prominent players operating in the global DNA synthesis market are:
DNA Synthesis Market Strategic Developments
DNA synthesis, also known as DNA replication or DNA replication, is the process by which a cell duplicates its DNA to produce two identical copies.
The global DNA synthesis market was valued at US$ 3.01 billion in 2022.
The estimated market size of the global DNA synthesis market in 2031 is US$ 14.56 billion.
The revenue CAGR of the DNA synthesis market during the forecast period will be 19.13% from 2023 to 2031.
Some key companies operating in the global DNA synthesis market are IBA Lifesciences GmbH, Biomatik, Integrated DNA Technologies Inc., Quintara Biosciences, GenScript Biotech Corporation, and OriGene Technologies Inc.
*Insights on financial performance are subject to the availability of information in the public domain